Skip to content
Accessibility help
Search NICE…
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Deferred
Awaiting development
Topic prioritisation
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Type
Type
Guidance (91)
Guidance programme
Guidance programme
Early value assessment (1)
HealthTech guidance (2)
Technology appraisal guidance (89)
HealthTech approach
HealthTech approach
Early use (1)
Apply filters
Showing 31 to 40 of 91
Keyword or reference number: cancer
`Remove $Keyword or reference number: cancer filter`
Guidance and quality standards awaiting development
Title
Type
Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast
cancer
after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment [ID6576]
Technology appraisal guidance
Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast
cancer
after a CDK 4-6 inhibitor [ID6650]
Technology appraisal guidance
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung
cancer
after a tyrosine kinase inhibitor [ID6305]
Technology appraisal guidance
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate
cancer
after an anti-androgen but not a taxane [ID6743]
Technology appraisal guidance
Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate
cancer
after abiraterone acetate [ID6677]
Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate
cancer
[ID6595]
Technology appraisal guidance
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder
cancer
[ID6321]
Technology appraisal guidance
Olomorasib in combination for untreated KRAS G12C mutation-positive unresectable advanced non-squamous non-small-cell lung
cancer
[GID-TA12001]
Technology appraisal guidance
Olomorasib with pembrolizumab for untreated KRAS G12C mutation- and PD-L1-positive unresectable advanced non-small-cell lung
cancer
[GID-TA12003]
Technology appraisal guidance
Ovarian, fallopian tube, peritoneal
cancer
(platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]
Technology appraisal guidance
Previous page
1
2
3
Current page
4
5
6
…
10
Page
4
of
10
Next page
Results per page
10
25
50
All
Back to top